These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 28821270)

  • 1. Calmodulin-like protein 3 is an estrogen receptor alpha coregulator for gene expression and drug response in a SNP, estrogen, and SERM-dependent fashion.
    Qin S; Ingle JN; Liu M; Yu J; Wickerham DL; Kubo M; Weinshilboum RM; Wang L
    Breast Cancer Res; 2017 Aug; 19(1):95. PubMed ID: 28821270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ZNF423 modulates the AMP-activated protein kinase pathway and metformin response in a single nucleotide polymorphisms, estrogen and selective estrogen receptor modulator dependent fashion.
    Qin S; Ingle JN; Kim W; Gao H; Weinshilboum RM; Wang L
    Pharmacogenet Genomics; 2021 Sep; 31(7):155-164. PubMed ID: 34001842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 4-Hydroxytamoxifen enhances sensitivity of estrogen receptor α-positive breast cancer to docetaxel in an estrogen and ZNF423 SNP-dependent fashion.
    Wang G; Qin S; Zayas J; Ingle JN; Liu M; Weinshilboum RM; Shen K; Wang L
    Breast Cancer Res Treat; 2019 Jun; 175(3):567-578. PubMed ID: 30937657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention.
    Ingle JN; Liu M; Wickerham DL; Schaid DJ; Wang L; Mushiroda T; Kubo M; Costantino JP; Vogel VG; Paik S; Goetz MP; Ames MM; Jenkins GD; Batzler A; Carlson EE; Flockhart DA; Wolmark N; Nakamura Y; Weinshilboum RM
    Cancer Discov; 2013 Jul; 3(7):812-25. PubMed ID: 23764426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SNPs near the cysteine proteinase cathepsin O gene (CTSO) determine tamoxifen sensitivity in ERα-positive breast cancer through regulation of BRCA1.
    Cairns J; Ingle JN; Wickerham LD; Weinshilboum R; Liu M; Wang L
    PLoS Genet; 2017 Oct; 13(10):e1007031. PubMed ID: 28968398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-dimensional oxabicycloheptene sulfonate targets the homologous recombination and repair programmes through estrogen receptor α antagonism.
    Wu J; Yan J; Fang P; Zhou HB; Liang K; Huang J
    Cancer Lett; 2020 Jan; 469():78-88. PubMed ID: 31629931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ZNF423: A New Player in Estrogen Receptor-Positive Breast Cancer.
    Bond HM; Scicchitano S; Chiarella E; Amodio N; Lucchino V; Aloisio A; Montalcini Y; Mesuraca M; Morrone G
    Front Endocrinol (Lausanne); 2018; 9():255. PubMed ID: 29867779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the
    Liu D; Ho MF; Schaid DJ; Scherer SE; Kalari K; Liu M; Biernacka J; Yee V; Evans J; Carlson E; Goetz MP; Kubo M; Wickerham DL; Wang L; Ingle JN; Weinshilboum RM
    NPJ Breast Cancer; 2017; 3():30. PubMed ID: 28856246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting estrogen receptor-α reduces adrenocortical cancer (ACC) cell growth in vitro and in vivo: potential therapeutic role of selective estrogen receptor modulators (SERMs) for ACC treatment.
    Sirianni R; Zolea F; Chimento A; Ruggiero C; Cerquetti L; Fallo F; Pilon C; Arnaldi G; Carpinelli G; Stigliano A; Pezzi V
    J Clin Endocrinol Metab; 2012 Dec; 97(12):E2238-50. PubMed ID: 23074235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PARP-1 Regulates Estrogen-Dependent Gene Expression in Estrogen Receptor α-Positive Breast Cancer Cells.
    Gadad SS; Camacho CV; Malladi V; Hutti CR; Nagari A; Kraus WL
    Mol Cancer Res; 2021 Oct; 19(10):1688-1698. PubMed ID: 34158394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of a single-nucleotide polymorphism near the CTSO gene in hormone receptor-positive breast cancer patients.
    Hato Y; Kondo N; Yoshimoto N; Endo Y; Asano T; Dong Y; Nishimoto M; Takahashi S; Fujii Y; Nakanishi R; Toyama T
    Int J Clin Oncol; 2016 Jun; 21(3):539-47. PubMed ID: 26482374
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Ho MF; Ingle JN; Bongartz T; Kalari KR; Goss PE; Shepherd LE; Mushiroda T; Kubo M; Wang L; Weinshilboum RM
    Mol Pharmacol; 2017 Aug; 92(2):175-184. PubMed ID: 28615284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiRNA-27a sensitizes breast cancer cells to treatment with Selective Estrogen Receptor Modulators.
    Ljepoja B; García-Roman J; Sommer AK; Wagner E; Roidl A
    Breast; 2019 Feb; 43():31-38. PubMed ID: 30415143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
    Wardell SE; Ellis MJ; Alley HM; Eisele K; VanArsdale T; Dann SG; Arndt KT; Primeau T; Griffin E; Shao J; Crowder R; Lai JP; Norris JD; McDonnell DP; Li S
    Clin Cancer Res; 2015 Nov; 21(22):5121-5130. PubMed ID: 25991817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen, SNP-Dependent Chemokine Expression and Selective Estrogen Receptor Modulator Regulation.
    Ho MF; Bongartz T; Liu M; Kalari KR; Goss PE; Shepherd LE; Goetz MP; Kubo M; Ingle JN; Wang L; Weinshilboum RM
    Mol Endocrinol; 2016 Mar; 30(3):382-98. PubMed ID: 26866883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential estradiol and selective estrogen receptor modulator (SERM) regulation of Keratin 13 gene expression and its underlying mechanism in breast cancer cells.
    Sheng S; Barnett DH; Katzenellenbogen BS
    Mol Cell Endocrinol; 2008 Dec; 296(1-2):1-9. PubMed ID: 18951949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice.
    O'Regan RM; Osipo C; Ariazi E; Lee ES; Meeke K; Morris C; Bertucci A; Sarker MA; Grigg R; Jordan VC
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2255-63. PubMed ID: 16609042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer.
    Traphagen NA; Schwartz GN; Tau S; Roberts AM; Jiang A; Hosford SR; Marotti JD; Goen AE; Romo BA; Johnson AL; Duffy EK; Demidenko E; Heverly P; Mosesson Y; Soucy SM; Kolling F; Miller TW
    Clin Cancer Res; 2023 Sep; 29(18):3717-3728. PubMed ID: 37439680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanisms of selective estrogen receptor modulator activity in human breast cancer cells: identification of novel nuclear cofactors of antiestrogen-ERα complexes by interaction proteomics.
    Cirillo F; Nassa G; Tarallo R; Stellato C; De Filippo MR; Ambrosino C; Baumann M; Nyman TA; Weisz A
    J Proteome Res; 2013 Jan; 12(1):421-31. PubMed ID: 23170835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear receptor modulation--role of coregulators in selective estrogen receptor modulator (SERM) actions.
    Feng Q; O'Malley BW
    Steroids; 2014 Nov; 90():39-43. PubMed ID: 24945111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.